KMT2A rearrangements are present in 2% of pediatric BCP-ALL > 1 year old and represent a poor prognostic factor, though recent studies showed that menin inhibitors are promising therapeutic options [3, 4]. Here, KMT2A is linked to acute lymphoblastic leukemia.